Stempeutics receives ODD in the European Union for Stempeucel

01 Jun 2015 Evaluate

Stempeutics Research, a group company of Manipal Education & Medical Group and a Joint Venture (JV) with Cipla Group, has received Orphan Drug Designation for its drug Stempeucel for the treatment of Thromboangiitis Obliterans from the European Medicines Agency (EMA).

Thromboangiitis obliterans or Buerger’s Disease is a rare and severe disease affecting the blood vessels of the legs. It is characterized by inflammation and occlusion of the vessels of extremities resulting in reduced blood flow to these areas, thus leading to severe pain and ulcers or necrosis, which finally may require amputation. Stempeucel treatment is designed to enhance the body's limited capability to restore blood flow in ischemic tissue by reducing inflammation and improving neovascularization.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1328.25 15.40 (1.17%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×